|
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling
|
|
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
|
|
Defining Waldenström's Macroglobulinemia
|
|
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations
|
|
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications
|
|
Novel biologically based therapies for Waldenstrom's macroglobulinemia
|
|
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
|
|
Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias
|
|
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells
|
|
The malignant clone in Waldenstrom's macroglobulinemia
|
|
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
|
|
Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
|
